Boston Scientific Corp
NYSE:BSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lakes Blue Energy NL
OTC:LKOLF
|
AU |
|
M
|
Mkango Resources Ltd
OTC:MKNGF
|
CA |
|
Devonian Health Group Inc
OTC:DVHGF
|
CA |
|
Greater Cannabis Company Inc
OTC:GCAN
|
US |
|
C
|
Chinney Investments Ltd
HKEX:216
|
HK |
Boston Scientific Corp
Narrow
Economic Moat
Boston Scientific Corp has a narrow economic moat due to its strong portfolio of patents and reputation in the medical technology industry, as well as its position in specialized market segments where competition is naturally limited.
Boston Scientific Corp
Competitive Advantages
Boston Scientific possesses a variety of patents and a well-established brand in the medical technology industry. These intangible assets help protect against competition and support product innovation.
The company operates in specialized segments of the medical device industry, where only a few players can sustain due to high technological barriers and regulatory hurdles, limiting competition.
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$188.63 |
+0.9%
|
$4.6T | Wide |
|
|
|
Apple Inc
AAPL
|
$260.48 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$317.24 |
-0.2%
|
$3.8T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$370.87 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$238.38 |
+1.8%
|
$2.6T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 985 |
+2.6%
|
$1.6T | Wide |
|
|
|
Meta Platforms Inc
META
|
$629.86 |
+0.1%
|
$1.6T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$371.55 |
-2.1%
|
$1.8T | Wide |
|
|
|
Walmart Inc
WMT
|
$126.77 |
+0.6%
|
$1T | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$939.47 |
-1.3%
|
$888.2B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
Advantest Corp
6857
|
¥24 990 |
+7.3%
|
$118.3B | Wide |
|
|
|
Eoptolink Technology Inc Ltd
300502
|
¥522.5 |
+2.7%
|
$75.5B | Wide |
|
|
|
Disco Corp
6146
|
¥66 890 |
+5.3%
|
$46.9B | Wide |
|
|
G
|
Gold Fields Ltd
GFI
|
Zac80 076 |
-1.5%
|
$44.9B | Wide |
|
|
|
Suzhou TFC Optical Communication Co Ltd
300394
|
¥358.9 |
-4.1%
|
$40.5B | Wide |
|
|
|
GE Healthcare Technologies Inc
GEHC
|
$73.18 |
+0%
|
$33.4B | Wide |
|
|
|
Hindustan Aeronautics Ltd
HAL
|
₹4 113.6001 |
+0.8%
|
$30.3B | Wide |
|
|
|
Bajaj Auto Ltd
BAJAJ-AUTO
|
₹9 828 |
+2.6%
|
$30.2B | Wide |
|
|
F
|
Fortress Transportation and Infrastructure Investors LLC
FTAI
|
$251.42 |
+5.8%
|
$25.8B | Wide |
|
|
|
Lasertec Corp
6920
|
¥41 580 |
+2.4%
|
$25.3B | Wide |
Boston Scientific Corp
Glance View
In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat